No CYP-affinity. No conceivable effects on PXR activation. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Panitumumab is a recombinant human IgG2 kappa monoclonal antibody that specifically binds to the human epidermal growth factor receptor (EGFR, HER1, c-erbB-1).

Panitumumab is an antineoplastic agent used in the treatment of colorectal cancer metastases with wild type KRAS after chemotherapeutic failure. It is administered as an intravenous infusion. Common adverse reactions of panitumumab that can be confused with an acute porphyric attack are diarrhoea, nausea, vomiting, and dyspnoea. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Panitumumab is metabolized in the same way as endogenous IgG. Non-CYP metabolism.